Our recent efforts to explore the sensitivity factors for cisplatin treatment in NPC cells have revealed that asparagine synthetase, matrix metalloproteinase 19, and eIF3a confer cisplatin sensitivity to NPC cells [9], [10]. The gene discussed is ASNS; the disease is nasopharyngeal carcinoma.